Interim 48-month data show 86% of patients with glaucoma or ocular hypertension remain off topical drops after a single cataract procedure, although the drop-free rate has eased from earlier timepoints.
|Articles|November 13, 2018
J&J Vision Practice Profile Series
Advertisement
Refractive Cataract Surgery: Creating a new paradigm with extended-depth-of-focus IOL technology
Patients eligible for IOL technologies want a full range of vision, good visual acuity, and limited time wearing glasses. Read how this IOL provides excellent far and close-range vision.
Advertisement
Related to this article
CLARITY program data show significantly longer time to treatment failure and higher rates of steroid-free quiescence vs placebo.
Drs Bryce St. Clair and Behrad Garmsiri explain how they build trust, improve health literacy, and destigmatize future interventions for patients with AMD.
Diana Canto-Sims, OD, introduces the second guest of Season 2, Raphael Rostenne, who will be discussing AI-assisted front desk management.
Duravyu gained 2.5 letters vs 6.1 with aflibercept at week 52/56, missing noninferiority in a second phase 3 wet AMD trial.
Alcon's Brytly eye drops received FDA approval for OTC temporary relief of minor ocular redness.
From dry eye to GLP-1s, this year's conference brought a variety of insights from key experts in optometry.
Ryzumvi gained a presbyopia indication in adults based on the phase 3 VEGA-2 and VEGA-3 trials, adding a pharmacologic option for managing near vision loss.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
More than monitoring: Using AMD visits to promote healthy vision aging
2
Brepocitinib for noninfectious uveitis meets all phase 3 trial end points
3
BIM-IOL System holds 37% IOP reduction at 4 years in first-in-human trial
4
FDA approves Brytly eye drops for ocular redness relief lasting up to 12 hours
5